From the first days of annexation of Crimea and launch of the military operation in the east of Ukraine, Alliance for Public Health (hereinafter – Alliance) defined that one of its priorities was support of HIV, tuberculosis, viral hepatitis prevention and treatment programs, as well ...

European Medicines Agency validates Gilead’s Marketing Authorization Application for investigational chronic hepatitis C therapy sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) SOF/VEL/VOX granted an accelerated assessment by the European Medicines Agency FOSTER CITY, Calif., Jan. 20, 2017– Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Marketing Authorization Application (MAA) for ...

Kaiser Family Foundation: The Global HIV/AIDS Epidemic This updated fact sheet provides information on current HIV prevalence and incidence, prevention and treatment strategies, and the U.S. and global responses to the epidemic (1/19). Kaiser Family Foundation: The U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) This updated fact ...

Long-term care for an aging HIV population is uncharted territory, as researchers and physicians are seeing the effects of the first wave of individuals who have been on antiretroviral therapy (ART) for a significant period of time. An increasing amount of academic and clinical research has ...

Providing pre-exposure prophylaxis (PrEP) to people who need it entails at least nine key steps, which can be conceived of as a PrEP continuum of care, according to an article published online ahead of print by Amy Nunn and colleagues in AIDS. This continuum can ...

Targeting chronic hepatitis B infections affecting more than 240 million people worldwide GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today (January 17) that it has entered into a research collaboration agreement with Georgia State University Research Foundation (GSU) to advance the ...

Health systems across Europe are confronting significant challenges. Ageing populations, a rising burden of chronic disease, and a more challenging fiscal context following the economic crisis, are focusing attention on the financial sustainability of health systems. There is a pressing need for solutions and tools ...

Researchers at University of California San Diego School of Medicine, with colleagues at the National Institute of Diabetes and Digestive and Kidney Diseases, the University of Manitoba and St. Boniface Hospital Albrechtsen Research Centre in Canada, have identified a molecular signaling pathway that, when blocked, ...

The long arm of the pharmaceutical industry continues to pervade practically every area of medicine, reaching those who write guidelines that shape doctors’ practices, patient advocacy organizations, letter writers to the Centers for Disease Control and Prevention and even oncologists on Twitter, according to a ...

A research team led by investigators of the Rockefeller University in New York and Prof Florian Klein, University Hospital Cologne and German Center for Infection Research (DZIF), has tested a new HIV neutralising antibody, called 10-1074, in humans. The results of the trial have just ...

Prohibition can prevent access to harm reduction treatment, including methadone, for people who inject drugs, writes Michel Kazatchkine Why is eastern Europe the only region in the world that still has a growing HIV epidemic?1 In one of the region’s countries, Russia, more than two thirds ...

The antiretroviral drugs used to treat HIV infection might inadvertently be boosting gay/bisexual men’s susceptibility to the bacteria responsible for syphilis, Treponema pallidum, conclude researchers in the journal Sexually Transmitted Infections. This might explain why new and repeat cases in these groups have risen so sharply ...

The vast majority of people taking antiretroviral therapy (ART) in the UK have an accurate knowledge of their current viral load (VL) level, investigators report in HIV Medicine. Overall, 96% of people who told researchers their viral load was undetectable had a clinic-recorded viral load ...

On January 16 the Scottish Medicines Consortium (SMC) published advice accepting Zepatier for routine use in NHS Scotland. Elbasvir-grazoprevir (Zepatier) was accepted for the treatment of chronic hepatitis C. Elbasvir-grazoprevir is a combination of two medicines that inhibit the replication of the hepatitis C virus and ...

The January issue of the Journal includes papers on a range of topics and reports from two recent meetings – the Ghent HIV Reservoir Characterization Symposium and the Third Biennial Strategies for an HIV Cure Meeting. To read an overview of the issue, click here. The January ...

Last month’s announcement that the Bill and Melinda Gates Foundation will give up to $140 million to a Boston drug device manufacturer to develop an implantable mini-pump to deliver drugs for pre-exposure prophylaxis (PrEP) against HIV infection has focused attention on the future of PrEP. ...

Washington, DC – January 13, 2017 – A clever new tuberculosis vaccine has shown promise in trials in mice. If it succeeds, it will be the first new TB vaccine in a century. With the rise of multidrug resistant tuberculosis, the difficulty of curing the ...

Dramatic decrease of funding from donors for HIV and TB responses and inability or unwillingness of governments to finance such programs has devastating effects on key affected populations (KAPs) in middle-income countries (MICs) – sex workers, men who have sex with men, people who use ...